• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 3, 2015

View Archived Issues

UK: Gene editing OK in research; discussion needed for clinical use

LONDON – The UK's major medical research bodies have come out in favor of the use of gene editing in preclinical research, including the use of the technology in human reproductive cells and early embryos. Read More

Amgen pairs with Novartis in a deal targeting Alzheimer's, migraines

A risk-defraying pact between Amgen Inc. and Novartis AG will align the companies' early stage efforts to fight Alzheimer's disease (AD) behind Novartis' phase I/II oral beta-site APP-cleaving enzyme-1 (BACE) inhibitor, CNP-520, while also enlisting Novartis as a co-developer and eventual co-seller of Amgen's two migraine candidates in markets beyond North America and Japan. Read More

Nanoparticle quells inflammation in sepsis and ARDS

Researchers at Queens University Belfast have developed a nanoparticle that could dampen inflammatory responses and improve survival in animal models of both sepsis and acute respiratory distress syndrome, both major causes of death and disability in hospitalized patients. Read More

Incyte buys into future with potential $795M Jiangsu Hengrui deal

Incyte Corp. leveraged its positive cash flow to invest in its immuno-oncology (I-O) future through a license and collaboration agreement with Jiangsu Hengrui Medicine Co. Ltd. to develop and commercialize anti-PD-1 monoclonal antibody SHR-1210. Read More

ADC Therapeutics adds $80M on march to clinic; lead drug in lymphoma

LONDON – Having moved its lead antibody-drug conjugate (ADC) into phase I over the summer, ADC Therapeutics Sarl has raised $80 million in a private round to fund that program and to take six further products into the clinic. Read More

Regulatory front

In another victory for biopharma, the Patent and Trademark Office (PTO) rejected a second inter partes review (IPR) petition filed against a drugmaker by a hedge fund manager. Read More

Stock movers

Read More

Financings

Aytu Bioscience Inc., of Englewood, Colo., closed the final tranche of its planned private placement convertible note financing, raising a total of about $5.1 million, which includes proceeds from two prior tranches totaling about $3.1 million. Read More

Other news to note

Baxalta Inc., of Bannockburn, Ill., filed SEC paperwork for a secondary offering of up to $1.45 billion of common stock of the company currently held by Baxter International Inc., of Deerfield, Ill. Read More

Appointments and advancements

Crispr Therapeutics, of Basel, Switzerland, named Samarth Kulkarni chief business officer, and Michael Bruce senior vice president, program portfolio and alliance management. Read More

In the clinic

Intra-Cellular Therapies Inc., of New York, said results published in Biological Psychiatry from a phase II trial of ITI-007 in patients with schizophrenia showed the drug significantly improved symptoms in patients experiencing an acute exacerbation of schizophrenia at a dose of 60 mg daily, as demonstrated by a statistically significant separation from placebo on the Positive and Negative Syndrome Scale (PANSS) total score at four weeks, the primary endpoint. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe